Alison L. Hannah, MD

Alison has served as a director since June 2015. She has over 25 years of experience in the development of investigational cancer chemotherapies. Since 2000, she has served as a consultant to the pharmaceutical industry, working with over 20 companies with a focus on molecularly targeted therapy. Prior to this, she worked as Senior Medical Director at SUGEN on various compounds, including SUTENT® (sunitinib malate), and Quintiles (now IQVIA), a global contract research organization. Alison specializes in clinical development strategy and has filed over 30 Investigational New Drug (IND) applications for new molecular entities and 7 New Drug Applications (NDAs). She participates in data monitoring committees, scientific advisory boards, and independent review committees for clinical trials. She has a BS in biochemistry and immunology from Harvard University and her MD from the University of Saint Andrews. She is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the American Society of Hematology (ASH), and the European Society for Medical Oncology (ESMO), and a Fellow with the Royal Society of Medicine (RSM).